Abacavir/lamivudine - GlaxoSmithKline/ViiV Healthcare

Drug Profile

Abacavir/lamivudine - GlaxoSmithKline/ViiV Healthcare

Alternative Names: Epivir/ziagen; EPZICOM; Kivexa; lamivudine/abacavir; Ziagen/Epivir

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline; ViiV Healthcare
  • Developer GlaxoSmithKline; Mylan; ViiV Healthcare
  • Class Antiretrovirals; Cyclopentanes; Cyclopropanes; Dideoxynucleosides; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action HIV replication inhibitors; Nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed HIV infections

Most Recent Events

  • 16 Jan 2018 Abacavir/lamivudine is still tentatively approved for HIV infections (In children, In infants, In neonates) in USA (PO) (US FDA website (PEPFAR), January 2018)
  • 15 Dec 2016 Biomarkers information updated
  • 05 Aug 2011 ViiV healthcare files lawsuit against Teva Pharmaceutical for infringing patent US 6 417 191
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top